The two studies, Zodiac (Zactima in combination with docetaxel in non-small cell lung cancer) and Zeal (Zactima efficacy with alimta in lung cancer), are the second and third of four ongoing studies to complete enrollment. Data from the studies are expected later this year and the broad development program is on track for a first regulatory submission in 2008.
Zodiac and Zeal are part of a broad Phase III clinical trial program designed to gain an understanding of how Zactima (vandetanib) may benefit people with lung cancer.